Merck Launches Phase III Study for KRAS Hopeful, Eyes Challenge to Amgen and BMS

Merck on Thursday launched a Phase III trial that will evaluate its oral KRAS inhibitor candidate MK-1084 in non-small cell lung cancer patients carrying the G12C mutation in the KRAS gene.